title: Endogenous urinary monoamine oxidase inhibitor excretion in Parkinson's disease and other neurological disorders.
abstract: In this study, urinary output of both neutral (tribulin) and basic monoamine oxidase inhibitory activity was measured in parkinsonian patients, other neurological patients and controls. No significant differences in output were found between these different groups. In general, tribulin output rose with age, in parallel with known changes in monoamine oxidase B activity.
authors.affiliation: Bernhard Baron Memorial Research Laboratories, Queen Charlotte's Hospital, London, U.K.
authors.forename: A
authors.initials: A
authors.lastname: Ueki
authors.forename: J
authors.initials: J
authors.lastname: Willoughby
authors.forename: V
authors.initials: V
authors.lastname: Glover
authors.forename: M
authors.initials: M
authors.lastname: Sandler
authors.forename: K
authors.initials: K
authors.lastname: Stibbe
authors.forename: G M
authors.initials: GM
authors.lastname: Stern
mesh_terms: D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000378:metabolism*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D007510:Isatin; D008297:Male; D008875:Middle Aged; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use / Q000652:urine*; D009422:Nervous System Diseases / Q000188:drug therapy* / Q000652:urine; D010300:Parkinson Disease / Q000188:drug therapy* / Q000652:urine
chemical_list: D008996:Monoamine Oxidase Inhibitors; D007510:Isatin; C039776:tribulin; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine